Login to Your Account



4SC in $192M Agreement for Japan Rights to Resminostat

By Cormac Sheridan


Friday, April 15, 2011
Setting down a weighty marker for partnering deals elsewhere, 4SC AG is pocketing €6 million (US$8.7 million) up front and could earn another €127 million in milestones, for licensing Japanese rights to its oral pan-histone deacetylase (HDAC) inhibitor resminostat (4SC-201).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription